Kronisk myeloisk leukemi : Förebild för målstyrd terapi
Vid kronisk myeloisk leukemi har målstyrd, kontinuerlig behandling med tyrosinkinashämmare lett till dramatiskt förbättrad överlevnad.Chronic myeloid leukemia (CML) pioneered as the first human malignancy linked to a specific cytogenetic aberration (the Philadelphia chromosome), which led the way to specific targeted therapies with imatinib (Glivec) and later tyrosine kinase inhibitors (TKI). Continuous TKI administration, blocking the oncogenic fusion protein Bcr-Abl, has revolutionized the outcome of CML, transforming an almos
